Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76


A highly specific SpCas9 variant is identified by in vivo screening in yeast.

Casini A, Olivieri M, Petris G, Montagna C, Reginato G, Maule G, Lorenzin F, Prandi D, Romanel A, Demichelis F, Inga A, Cereseto A.

Nat Biotechnol. 2018 Mar;36(3):265-271. doi: 10.1038/nbt.4066. Epub 2018 Jan 29.


Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development.

Bruno W, Andreotti V, Bisio A, Pastorino L, Fornarini G, Sciallero S, Bianchi-Scarrà G, Inga A, Ghiorzo P.

PLoS One. 2017 Dec 7;12(12):e0189123. doi: 10.1371/journal.pone.0189123. eCollection 2017.


Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity.

Andrysik Z, Galbraith MD, Guarnieri AL, Zaccara S, Sullivan KD, Pandey A, MacBeth M, Inga A, Espinosa JM.

Genome Res. 2017 Oct;27(10):1645-1657. doi: 10.1101/gr.220533.117. Epub 2017 Sep 13.


Inherited determinants of early recurrent somatic mutations in prostate cancer.

Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P, Gasperini P, Cereseto A, Elemento O, Sboner A, Khurana E, Inga A, Rubin MA, Demichelis F.

Nat Commun. 2017 Jun 29;8(1):48. doi: 10.1038/s41467-017-00046-0.


DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.

Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.

Mol Oncol. 2017 Jun;11(6):612-627. doi: 10.1002/1878-0261.12051. Epub 2017 May 2.


The structure formed by inverted repeats in p53 response elements determines the transactivation activity of p53 protein.

Brázda V, Čechová J, Battistin M, Coufal J, Jagelská EB, Raimondi I, Inga A.

Biochem Biophys Res Commun. 2017 Jan 29;483(1):516-521. doi: 10.1016/j.bbrc.2016.12.113. Epub 2016 Dec 19.


Human transcription factors in yeast: the fruitful examples of P53 and NF-кB.

Sharma V, Monti P, Fronza G, Inga A.

FEMS Yeast Res. 2016 Nov;16(7). pii: fow083. Epub 2016 Sep 27. Review.


c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.

Ciribilli Y, Singh P, Inga A, Borlak J.

Oncotarget. 2016 Oct 4;7(40):65514-65539. doi: 10.18632/oncotarget.11804.


The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial-Mesenchymal Transition in Breast Cancer.

Latorre E, Carelli S, Raimondi I, D'Agostino V, Castiglioni I, Zucal C, Moro G, Luciani A, Ghilardi G, Monti E, Inga A, Di Giulio AM, Gorio A, Provenzani A.

Cancer Res. 2016 May 1;76(9):2626-36. doi: 10.1158/0008-5472.CAN-15-2018. Epub 2016 Apr 20.


Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.

Soares J, Raimundo L, Pereira NA, Monteiro Â, Gomes S, Bessa C, Pereira C, Queiroz G, Bisio A, Fernandes J, Gomes C, Reis F, Gonçalves J, Inga A, Santos MM, Saraiva L.

Oncotarget. 2016 Jan 26;7(4):4326-43. doi: 10.18632/oncotarget.6775.


The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma.

Andreotti V, Bisio A, Bressac-de Paillerets B, Harland M, Cabaret O, Newton-Bishop J, Pastorino L, Bruno W, Bertorelli R, De Sanctis V, Provenzani A, Menin C, Fronza G, Queirolo P, Spitale RC, Bianchi-Scarrà G, Inga A, Ghiorzo P.

Pigment Cell Melanoma Res. 2016 Mar;29(2):210-21. doi: 10.1111/pcmr.12444. Epub 2015 Dec 17.


The 5'-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding.

Bisio A, Latorre E, Andreotti V, Bressac-de Paillerets B, Harland M, Scarra GB, Ghiorzo P, Spitale RC, Provenzani A, Inga A.

Oncotarget. 2015 Nov 24;6(37):39980-94. doi: 10.18632/oncotarget.5387.


Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.

Leão M, Soares J, Gomes S, Raimundo L, Ramos H, Bessa C, Queiroz G, Domingos S, Pinto M, Inga A, Cidade H, Saraiva L.

Life Sci. 2015 Dec 1;142:60-5. doi: 10.1016/j.lfs.2015.10.015. Epub 2015 Oct 21.


Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.

Ciribilli Y, Singh P, Spanel R, Inga A, Borlak J.

Oncotarget. 2015 Oct 13;6(31):31569-92. doi: 10.18632/oncotarget.5035.


RiboAbacus: a model trained on polyribosome images predicts ribosome density and translational efficiency from mammalian transcriptomes.

Lauria F, Tebaldi T, Lunelli L, Struffi P, Gatto P, Pugliese A, Brigotti M, Montanaro L, Ciribilli Y, Inga A, Quattrone A, Sanguinetti G, Viero G.

Nucleic Acids Res. 2015 Dec 15;43(22):e153. doi: 10.1093/nar/gkv781. Epub 2015 Aug 3.


Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay.

Sharma V, Jordan JJ, Ciribilli Y, Resnick MA, Bisio A, Inga A.

PLoS One. 2015 Jul 6;10(7):e0130170. doi: 10.1371/journal.pone.0130170. eCollection 2015.


Whole-genome cartography of p53 response elements ranked on transactivation potential.

Tebaldi T, Zaccara S, Alessandrini F, Bisio A, Ciribilli Y, Inga A.

BMC Genomics. 2015 Jun 17;16:464. doi: 10.1186/s12864-015-1643-9.


Regulation of human PTCH1b expression by different 5' untranslated region cis-regulatory elements.

Ozretić P, Bisio A, Musani V, Trnski D, Sabol M, Levanat S, Inga A.

RNA Biol. 2015;12(3):290-304. doi: 10.1080/15476286.2015.1008929.


In-silico identification and functional validation of allele-dependent AR enhancers.

Garritano S, Romanel A, Ciribilli Y, Bisio A, Gavoci A, Inga A, Demichelis F.

Oncotarget. 2015 Mar 10;6(7):4816-28.


Evolution of p53 transactivation specificity through the lens of a yeast-based functional assay.

Lion M, Raimondi I, Donati S, Jousson O, Ciribilli Y, Inga A.

PLoS One. 2015 Feb 10;10(2):e0116177. doi: 10.1371/journal.pone.0116177. eCollection 2015.

Supplemental Content

Loading ...
Support Center